Raymond J. Hohl, M.D., Ph.D.
Holden Family Chair
Professor of Medicine and Pharmacology
Associate Chair, Department of Internal Medicine
Associate Director for Translational Research, Holden Comprehensive Cancer Center

Dr. Hohl's research interests focus on understanding the interactions between mevalonic acid and cholesterol biosynthesis and the proliferation of acute myeloid leukemia cells. These studies investigate the relative affinities of various growth regulating proteins, such as RAS and KREV1, for the isoprene intermediates of the mevalonic acid to cholesterol biosynthetic pathway. His clinical interests involve evaluation of the potential role for pharmacologic inhibitors of this biosynthetic pathway in the treatment of various hematologic malignancies and solid tumors. Additionally, he has continued interest in studying how various erythrocyte enzymothathies predispose the human red blood cell to drug-induced oxidative damage.

Honors, Awards, and Organizations

• Alpha Omega Alpha
• American Association for Cancer Research
• Diplomate, American Board of Internal Medicine, Board of Medical Oncology, and Hematology
• American College of Physicians, Fellow
• Carver Clinician Scientist Award, 1991
• American Society of Clinical Oncology, Young Investigator Award, 1992
• American Society of Hematology
• Paul E. Carson Pharmacology Award, 1988
• PMA Faculty Development Award in Clinical Pharmacology, 1992-95
• Outstanding Research Award-General Clinical Research Centers Program Directors' Association, 1996
• Laureate Award, Iowa Chapter of the American College of Physicians, 2001

Medical School:
Rush Medical College

Residency:
University of Chicago

Fellowship:
University of Chicago

Special Training:
Rush University, Pharmacology